GlobeNewswire·May 12, 2026, 4:05 PM ET

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

IBIO

iBio, Inc. received regulatory clearance from Australia's Therapeutic Goods Administration to initiate a Phase 1 clinical trial of IBIO-600 in overweight & obese adults, with first dosing expected in Q2 2026.
The company expanded its pipeline by engineering a selective bispecific antibody designed to block Activin A, GDF8 (myostatin), & GDF11 for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
New preclinical data from an obese non-human primate study showed IBIO-610 reduced visceral fat by 6.7% & total fat mass by 5.2% following twice-every-eight-week dosing.
Third fiscal quarter 2026 revenue was $0, while research & development expenses increased to $3.3 million & general & administrative expenses rose to approximately $5.1 million.
The increase in R&D expenses was driven by consultant costs, outside services for NHP studies & CMC activities, & higher personnel costs for advancing IBIO-600 & IBIO-610 programs.
General & administrative expenses included a $2.5 million impairment charge for the indefinite-lived intangible asset IBIO-101.
As of March 31, 2026, iBio held $74.8 million in cash, cash equivalents, & investments in debt securities, with a cash runway extending to Q4 fiscal year 2028.
The company received approximately $17 million in gross proceeds from warrant exercises during the fourth quarter of fiscal year 2026.
iBio presented data on AI-driven antibody drug discovery at the Drug R&D conference & participated in investor conferences including Biocom California, Leerink Global Healthcare, & Oppenheimer 36th Annual Healthcare Life Sciences.